Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Identification of Plasma Biomarkers for Brain Endothelial Function
Aging, Dementia, Cognitive, and Behavioral Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
BECs are important components of the blood-brain-barrier, and their dysfunction has been associated with cognitive impairment and dementia. However, these cells lack established blood biomarkers relevant for brain health. 
Identify plasma protein biomarkers of brain endothelial cells (BEC) that are related to clinically meaningful neurologic outcomes.
We used data from the Baltimore Longitudinal Study of Aging (BLSA) (n = 886) to identify BEC plasma biomarkers. Among the 7,268 plasma proteins measured on the SomaLogic ® platform, BEC proteins were identified using an automated annotation algorithm that filtered endothelial cell proteins form the Human Protein Atlas and cross-referenced previously published BEC-specific markers. We next identified a subset of BEC proteins associated with 3T MRI-defined white matter lesions; we then related this set of candidate proteins to white matter hyperintensities, lacunar infarcts, cerebral microhemorrhages and dementia risk in the Atherosclerosis Risk in Communities (ARIC) study. 
Of the 4,268 proteins examined, 28 proteins were categorized as BEC-specific, and four were significantly associated with white matter lesion volume (ICAM2, CDH5, CD93, GP1BB; p < 0.05), while another approached significance (RSPO3; p = 0.05). Of the three proteins measured in ARIC, two (CDH5, RSPO3) were related to white matter hyperintensities, cerebral microhemorrhages and dementia risk. Notably, the direction of association between CDH5 and RSPO3 with each outcome was consistent across studies. 
We identified novel plasma biomarkers of BECs that are associated with cerebral small vessel disease and dementia risk, particularly CDH5 (Cadherin 5) and RSPO3 (R-Spondin 3). Functional validation of these findings is warranted to further characterize the mechanisms underlying these relationships, and replication in additional external cohorts may support their use as blood biomarkers for brain health.
Jenifer Cordon (National Institute of Aging)
Miss Cordon has nothing to disclose.
Michael R. Duggan, PhD Dr. Duggan has nothing to disclose.
Heather Elizabeth Dark, PhD (NIA IRP) Dr. Dark has nothing to disclose.
Zhongsheng Peng, MD,PhD (NIA/NIH) Dr. Peng has nothing to disclose.
Krishna Pucha, Other Mr. Pucha has nothing to disclose.
Dimitrios Kapogiannis, MD The institution of Dr. Kapogiannis has received research support from National Institute on Aging (NIA/NIH).
Julian Candia, PhD (National Institute on Aging, NIH) Dr. Candia has nothing to disclose.
Gabriela Teresa Gomez Ms. Gomez has nothing to disclose.
Keenan Walker (Johns Hopkins School of Medicine) The institution of Keenan Walker has received research support from NIH.